Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:08:49 EDT Mon 16 Jun 2025
Enter Symbol
or Name
USA
CA



Q:CYDY - CYTODYN INC - https://www.cytodyn.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CYDY - Qnot subscribed0.35-0.0034-1.0851.72802450.3501  0.3575  0.330.4945  0.103115:59:59May 1515 min RT 2¢

Recent Trades - Last 10 of 245
Time ETExPriceChangeVolume
15:59:59Q0.35-0.0034100
15:59:38Q0.347-0.0064500
15:59:38Q0.3435-0.0099500
15:59:30Q0.3455-0.0079100
15:59:05Q0.34415-0.00925100
15:58:54Q0.3449-0.0085500
15:58:54Q0.345-0.0084400
15:58:18Q0.3473-0.0061100
15:57:23Q0.3435-0.0099300
15:56:11Q0.3455-0.0079100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-05-15 08:30U:CYDYNews ReleaseCytoDyn Releases ESMO Breast Cancer Meeting Poster
2025-05-13 08:30U:CYDYNews ReleaseCytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors
2025-05-06 08:30U:CYDYNews ReleaseCytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer
2025-04-29 08:30U:CYDYNews ReleaseCytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany
2025-03-18 08:30U:CYDYNews ReleaseMarch 2025 Letter to Shareholders
2025-02-24 08:30U:CYDYNews ReleaseCytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab
2025-02-06 08:30U:CYDYNews ReleaseCytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories
2024-12-17 08:30U:CYDYNews ReleaseDecember 2024 Letter to Shareholders
2024-11-25 08:30U:CYDYNews ReleaseCytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology
2024-11-04 08:30U:CYDYNews ReleaseCytoDyn Announces FDA Clearance of Its Phase II Oncology Trial
2024-10-30 08:30U:CYDYNews ReleaseCytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories
2024-10-08 08:30U:CYDYNews ReleaseCytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development
2024-10-07 11:05U:CYDYNews ReleaseCytoDyn Announces Abstract that Highlights Leronlimab's Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques
2024-10-04 08:30U:CYDYNews ReleaseCytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial
2024-09-24 08:30U:CYDYNews ReleaseCytoDyn Announces Preliminary Findings in Study with SMC Laboratories
2024-09-09 08:30U:CYDYNews ReleaseSeptember 2024 Letter to Shareholders
2024-08-23 08:30U:CYDYNews ReleaseCytoDyn Engages Leading CRO For Phase II Inflammation Trial
2024-08-12 08:30U:CYDYNews ReleaseCytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer
2024-07-09 08:30U:CYDYNews ReleaseCytoDyn Announces Settlement with Amarex Clinical Research LLC
2024-06-27 08:30U:CYDYNews ReleaseCytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024